【速递】默沙东发布HIF-2α抑制剂两项Ⅲ期肾细胞癌研究关键结果

九洲药业
Nov 07, 2025

2025 年 10 月 28 日,默沙东宣布了两项关于贝组替凡(Welireg)的 Ⅲ 期肾细胞癌研究关键结果,在肾细胞癌治疗领域引发广泛关注。这两项研究聚焦不同阶段的肾细胞癌患者,为该疾病的治疗策略带来了新的思路与方向。Jiuzhou News在 LITESPARK-011试验(晚期肾细胞癌)中,研究团队评估了双重口服疗法 Welireg(贝组替凡)联合仑伐替尼用于治疗既往接受抗 PD-1/L1...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10